The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 31 May 2012 up to and including 6 June 2012 the Company bought 900 own shares representing 0.00068% of the share capital of the Company, to the total value of BGN 2066.20 on the Bulgarian Stock Exchange. The average price per share was BGN 2.296.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 7 June 2012 up to and including 13 June 2012 the Company bought 4305 own shares representing 0.0033% of the share capital of the Company, to the total value of BGN 9749,25 on the Bulgarian Stock Exchange. The average price per share was BGN 2.265.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
On 14. June "Sopharma" received the prestigious international award "Business Partner of 2012". The award was given to the CEO Mr. Ognian Donev on a ceremony in Belgrade.
The award has been given sine 2008 by a panel of the academic community in Serbia, headed by Prof. Elias Chyosich, Dean of the Faculty of Technical Sciences in Novi Sad.
The categories in which the nominated companies competed are three: regional business partner, business partner of Serbia and media partner.
We would like to notify that the Annual General Meeting of shareholders of Sopharma AD, held on 19.06.2012 in Sofia, 16 Iliensko shousee, took the following decisions:
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 21 June 2012 up to and including 27 June 2012 the Company bought 15033 own shares representing 0.011% of the share capital of the Company, to the total value of BGN 33722.31 on the Bulgarian Stock Exchange. The average price per share was BGN 2.24.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
We would like to notify that for the month of June, 2012 Sopharma AD realized increase of sales revenues of 5% compared with the same month of the previous year, including increase of export sales of 10 % and 8% decrease of domestic sales.
During the first six months of this year Sopharma AD realized increase of sales revenues of 2%, including 12% decrease of domestic sales and 7% increase of export sales compared with the same period of 2011.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 19 July 2012 up to and including 25 July 2012 the Company bought 3435 own shares representing 0.0026% of the share capital of the Company, to the total value of BGN 7607.87 on the Bulgarian Stock Exchange. The average price per share was BGN 2.215.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 26 July 2012 up to and including 01 August 2012 the Company bought 10615 own shares representing 0.0080% of the share capital of the Company, to the total value of BGN 24752.28 on the Bulgarian Stock Exchange. The average price per share was BGN 2.32.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
Sopharma AD participated in the capital increase of Doverie Obedinen Holding AD and acquired 1 405 889 shares from the capital increase. As a result Sopharma AD has crossed the threshold of 15% in the capital of Doverie Obedinen Holding AD and now owns 18.697%.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 02 August 2012 up to and including 08 August 2012 the Company bought 4266 own shares representing 0.00323% of the share capital of the Company, at a total value of BGN 10025.00 on the Bulgarian Stock Exchange. The average price per share was BGN 2.35.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.